Oncology (Williston Park). 2019 Jul 16;33(7):629378.
Angiogenesis is known to play an important role in normal ovarian physiology as well as in growth and progression of ovarian cancer. The first FDA approval of bevacizumab in 2004 was for metastatic colorectal cancer in combination with chemotherapy; this was a key point for several subsequent approvals of antiangiogenic drugs. The efficacy of bevacizumab treatment is modest, however, and most ovarian cancer patients eventually develop acquired resistance, which highlights the need for new targeted therapies and/or combination strategies. Understanding the multitude of variables in response to antiangiogenic therapy would offer potential strategies for selecting patients most likely to benefit from such therapy.
血管生成在正常卵巢生理学以及卵巢癌的生长和进展中起着重要作用。贝伐珠单抗于 2004 年首次获得 FDA 批准，用于联合化疗治疗转移性结直肠癌；这是随后批准几种抗血管生成药物的关键要点。然而，贝伐珠单抗治疗的疗效是有限的，大多数卵巢癌患者最终会产生获得性耐药，这凸显了需要新的靶向治疗和/或联合策略。了解抗血管生成治疗反应的多种变量将为选择最有可能从这种治疗中获益的患者提供潜在策略。
